Humanigen Inc (HGENQ)

[oldberkeley]

That's always the question, of course.

Not a TA person myself, but I've never thought the idea of a gap that must be filled applies to bio's like this that drop because of a clinical trial fail. Oversold I'd agree with.

I'm looking at low-to-mid .50's sometime in February, at which point I'd be out for a 15-20% gain, good enough.

Best of luck.